RE:RE:RE:Dual approach of Tesamorelin… It also makes me wondevjust how important it is/was for THTX to allow these guys to get all these studies done.
I still think there is something of a leap of faith in where an F2/F3 population lands with the Ph3 biopsy endpoints but this data talks to that, it's sooooo directional. It's almost there.
The liver WILL get healthier if you take Tesamorelin. How much though? Enough to get approval?
qwerty22 wrote:
Grinspoon and his colleagues are just so productive, this reads great. Makes me wonder how much of all this they can incorporate into the Ph3.
scarlet1967 wrote: The article published today, it would be great to add a science section to the website adding these studies to it.
"In this study, we found that tesamorelin decreased plasma levels of VEGFA relative to placebo. Moreover, tesamorelin-treated participants who had the largest reduction in VEGFA demonstrated the greatest decline in NAS score. Angiogenesis plays a pivotal role in the pathogenesis of NAFLD. In this regard, liver biopsies from patients with NASH were found to exhibit significant neovascularization in proportion to the extent of fibrosis, whereas minimal neovascularization was observed in cases of simple steatosis12. VEGFA is a potent angiogenic factor that stimulates the proliferation, migration, and differentiation of endothelial cells. Studies have shown increased circulating levels13 and hepatic upregulation14 of VEGF in patients with NAFLD or NASH compared to controls. Conversely, blockade of VEGF receptor 2 was demonstrated to prevent and to treat hepatic steatosis and hepatocyte ballooning in mouse models of NASH15. Given the role of VEGFA in NAFLD pathogenesis, the reduction in this angiogenic factor by tesamorelin may in part underlie its attenuation of NAFLD progression in HIV. Whether VEGFA may serve as a biomarker in this regard merits further exploration in future studies."